Can’t see the audio player? Click here to listen on SoundCloud. White House chief of staff Mark Meadows said this week that “we’re not going to control the pandemic,” effectively conceding that the administration has pivoted from prevention to treatment. But COVID-19 cases are rising rapidly… Read More »KHN’s ‘What the Health?’: As Cases Spike, White House Declares Pandemic Over
La Casa Blanca y muchos estadounidenses han depositado sus esperanzas de derrotar a la pandemia de COVID-19 en una vacuna que se está desarrollando a la “velocidad de la luz”. Pero algunos científicos advierten que se espera demasiado, y demasiado pronto. “Todos piensan que COVID-19… Read More »Científicos advierten que se espera demasiado de una vacuna para COVID
Letters to the Editor is a periodic feature. We welcome all comments and will publish a selection. We edit for length and clarity and require full names. On the ‘Subject’ of Vaccine Trial Participants In the piece about the AstraZeneca vaccine trial subject who suffered severe spinal… Read More »Readers and Tweeters Shed Light on Vaccine Trials and Bias in Health Care
The White House and many Americans have pinned their hopes for defeating the COVID-19 pandemic on a vaccine being developed at “warp speed.” But some scientific experts warn they’re all expecting too much, too soon. “Everyone thinks COVID-19 will go away with a vaccine,” said… Read More »Scientists Warn Americans Are Expecting Too Much From a Vaccine
During the 40th week since the first coronavirus case appeared in the United States, worldwide cases surpassed the 41 million mark and U.S. cases are over 8 million and 223,000 deaths.
KHN chief Washington correspondent Julie Rovner discussed the impact of the election and the upcoming Supreme Court challenge on the Affordable Care Act with New Hampshire Public Radio’s “The Exchange” and WNYC’s “The Brian Lehrer Show” on Wednesday. Rovner also spoke with Newsy’s “Morning Rush”… Read More »KHN on the Air This Week
Is a century-old vaccine a ‘game-changer’ for COVID-19? Anita de Waard from Elsevier and Radoslav Kirkov from Estafet tells us how a hackathon is harnessing data science to look beyond the hype and seek definitive clinical evidence. Today, the notion of ‘data science’ has permeated… Read More »Data hackathon analyses truth behind TB vaccine and COVID-19
Shots: GSK reported that its RSV vaccines for maternal immunization (GSK3888550A) and older adults (GSK3844766A) were well-tolerated and highly immunogenic in P-I/II clinical studies. Both the candidate vaccines contain a recombinant RSVPreF3, that triggers the required immune response The GSK3844766A was first tested in 48… Read More »GSK Presents Results of Maternal & Older Adults RSV Vaccines at IDWeek 2020
If we really want to stem the spread of the coronavirus as winter looms and we wait for a vaccine, here’s an idea: The government should pay bars, many restaurants and event venues to close for some months. That may sound radical, but it makes… Read More »Analysis: Winter Is Coming for Bars. Here’s How to Save Them. And Us.
This brief examines key policy challenges and issues related to distributing a COVID-19 vaccine in the U.S., including funding, supply and logistics, federal, state, and local authorities, insurance coverage, addressing racial and ethnic disparities, and communication and trust.
Can’t see the audio player? Click here to listen on SoundCloud. President Donald Trump’s COVID-19 diagnosis — and that of two dozen or more other officials in the White House and Capitol Hill — has scrambled an already confusing autumn. The president’s illness has thrown into… Read More »KHN’s ‘What the Health?’: Trump vs. COVID
As America’s biopharmaceutical companies work around the clock to combat COVID-19, another virus with deadly consequences is right around the corner. The COVID-19 pandemic has led to more than 7.5 million infections and tragically more than 210,000 deaths. The influenza virus, more commonly known as… Read More »Flu Season 2020: Why it’s time to talk to your doctor today about getting a flu shot
The Trump administration’s pandemic response: decisive action that saved lives, or the greatest failure of any presidential administration? During Wednesday’s vice presidential debate, Vice President Mike Pence and the Democratic challenger, Sen. Kamala Harris of California, offered drastically different takes — from behind plexiglass screens… Read More »In Debate, Pence and Harris Offer Conflicting Views of Nation’s Reality
The guidance calls for a median two months’ worth of follow-up safety data from well-designed Phase III studies as a precondition for a vaccine receiving an EUA. The Wall Street Journal reported that the White House had backed down in its opposition to the guidance,… Read More »FDA issues Covid-19 vaccine guidance as White House reportedly relents
As trust in the Food and Drug Administration wavers, several states have vowed to conduct independent reviews of any COVID-19 vaccine the federal agency authorizes. But top health experts say such vetting may be misguided, even if it reflects a well-founded lack of confidence in… Read More »Distrusting Trump, States Plan to Vet COVID Vaccines Themselves. Bad Idea, Say Experts.
President Donald Trump makes no secret he would like a COVID-19 vaccine to be available before the election. But it’s doubtful that will happen and, even after a vaccine wins FDA approval, there would be a long wait before it’s time to declare victory over… Read More »5 Things to Know About a COVID Vaccine: It Won’t Be a ‘Magic Wand’
“Nearly 20% of cancer cases arising worldwide can be linked to infectious agents, including viruses.” Seven viruses are now conclusively tied to human cancers, and, as new viruses enter into human populations, the incidence and causes of cancer will likely change accordingly. The foundation of… Read More »The Role of Meat and Dairy Viruses in Cancer
Coming together to fight COVID-19: A conversation with Albert Bourla, Chairman & CEO of Pfizer, Inc.
Over the last seven months, our industry has been working around the clock to combat the COVID-19 virus, including developing potential therapeutics to treat COVID-19 and vaccines to prevent future infections.
La temporada de influenza se verá diferente este año, ya que los Estados Unidos se enfrentan a una pandemia de coronavirus que ya ha matado a más de 176.000 personas. Muchos estadounidenses son reacios a ir al médico y los funcionarios de salud pública temen… Read More »COVID + Influenza: éste es un buen año para vacunarse, aconsejan expertos
President Donald Trump accepted the Republican Party’s nomination for president in a 70-minute speech from the South Lawn of the White House on Thursday night. Speaking to a friendly crowd that didn’t appear to be observing social distancing conventions, and with few participants wearing masks,… Read More »Republican Convention, Day 4: Fireworks … and Shining a Light on Trump’s Claims
Flu season will look different this year, as the country grapples with a coronavirus pandemic that has killed more than 172,000 people. Many Americans are reluctant to visit a doctor’s office and public health officials worry people will shy away from being immunized. Although sometimes… Read More »COVID + Influenza: This Is a Good Year to Get a Flu Shot, Experts Advise
Moderna has said that its coronavirus vaccine stimulated an immune response in older people in phase 1 trials, suggesting that the jab is effective in the age groups most susceptible to COVID-19. An analysis of the latest data from a phase 1 trial showed that… Read More »Moderna’s COVID vaccine works in older people, according to new data
The patients at Dr. Eric Daar’s hospital are at high risk for serious illness from COVID-19, and he’s determined to make sure they’re part of the effort to fight the disease. He also hopes they can protect themselves in the process. When Daar and his… Read More »LA Hospital Seeks Vaccine Trial Participants Among Its Own High-Risk Patients
The biotech company reached a deal with the European Commission to supply an initial 80 million doses, while European Union member states will have the option to purchase 80 million more.
In a business driven by profit, vaccines have a problem. They’re not very profitable — at least not without government subsidies. Pharma companies favor expensive medicines that must be taken repeatedly and generate revenue for years or decades. Vaccines are often given only once or… Read More »Rather Than Give Away Its COVID Vaccine, Oxford Makes a Deal With Drugmaker
The latest: What they are saying: Intellectual property protections vital to incentivize ongoing COVID-19 research and development
America’s biopharmaceutical companies are committed to COVID-19 treatment and vaccine research and development (R&D). Reliable IP protections have helped drive innovation and enhance patient access to breakthrough therapies. Innovators are also relying on these strong protections to discover new medical advances that will keep patients… Read More »The latest: What they are saying: Intellectual property protections vital to incentivize ongoing COVID-19 research and development
Trump launches baseless attack on FDA; agency controversially authorizes plasma treatment for Covid-19
Over the weekend, Trump called the agency, without evidence, part of a “deep state” that was slow-walking vaccines and drugs for Covid-19. The next day, the agency authorized convalescent plasma despite having turned it down shortly before due to insufficient evidence.
The companies also said their Phase II/III study, slated to enroll about 30,000 participants, had already dosed more than 11,000.
New insights into smell and taste loss symptoms, artificial intelligence and further encouraging data from a vaccine candidate hit the headlines this week as the COVID-19 coronavirus pandemic continues. Here we highlight the biggest R&D, market access and digital coronavirus news of the past week.… Read More »Coronavirus pharma news round-up 21/08/20
Miles de cartas llenas de dinero inundaron el buzón de correo de Jonas Salk la semana después que su vacuna contra la polio fuera declarada segura y eficaz en 1955. Todo el mundo la quería. Los padres desesperados saturaban las líneas telefónicas de sus médicos… Read More »Confianza, miedo y solidaridad marcarán el éxito de una vacuna contra COVID
Thousands of letters stuffed with money flooded Jonas Salk’s mailbox the week after his polio vaccine was declared safe and effective in 1955. Everybody wanted his vaccine. Desperate parents clogged doctors’ phone lines in search of the precious elixir; drug companies and doctors diverted doses… Read More »Trust, Fear and Solidarity Will Determine the Success of a COVID Vaccine
MEDFORD, Ore. — From the outside, it appears to be just another suburban allergy clinic, a tidy, tan brick-and-cinder-block building set back from a busy highway and across the road from an auto parts store. But inside the offices of the Clinical Research Institute of… Read More »With COVID Vaccine Trial, Rural Oregon Clinic Steps Onto World Stage
Today, in honor of National Immunization Awareness Month, we’ll take a look at how Medicare Part D supports access to critical vaccines and strengthens public health. Vaccines represent some of the most impactful advances in public health, helping to prevent the spread of many infectious… Read More »Supporting access to vaccines for Part D beneficiaries
The agreement, which includes 100 million doses of mRNA-1273 and an option to acquire 400 million more, brings the total amount of money the biotech company has received from the federal government for its vaccine efforts to nearly $2.5 billion.
Dr. Eric Coe jumped at the chance to help test a COVID-19 vaccine. At his urging, so did his girlfriend, his son and his daughter-in-law. All received shots last week at a clinical research site in central Florida. “My main purpose in doing this was… Read More »Test Sites Quickly Attract Thousands for COVID-19 Vaccine Study
Para un mundo paralizado por el coronavirus, la salvación depende de una vacuna. Pero en los Estados Unidos, en donde al menos 4,6 millones de personas se han infectado y casi 155,000 han muerto, la promesa de esa vacuna se ve obstaculizada por otra epidemia… Read More »Epidemia de obesidad en los Estados Unidos amenaza la eficacia de una vacuna contra COVID
For a world crippled by the coronavirus, salvation hinges on a vaccine. But in the United States, where at least 4.6 million people have been infected and nearly 155,000 have died, the promise of that vaccine is hampered by a vexing epidemic that long preceded… Read More »America’s Obesity Epidemic Threatens Effectiveness of Any COVID Vaccine
Under the agreement with BARDA and the Department of Defense, the drugmaker would supply 100 million doses of its vaccine, for which it published preclinical data last and is currently running a first-in-human clinical trial.
With millions of lives on the line, researchers have been working at an unprecedented pace to develop a COVID-19 vaccine. But that speed — and some widely touted breakthroughs — belie the enormous complexity and potential risks involved. Researchers have an incomplete understanding of the… Read More »Fauci Unfazed as Scientists Rely on Unproven Methods to Create COVID Vaccines
The companies will provide 100 million doses of their jointly developed vaccine. But with a Phase I/II study planned in September, it is behind in development compared with those of Moderna and Pfizer and BioNTech, which have already started late-stage clinical testing.
Can’t see the audio player? Click here to listen on SoundCloud. President Donald Trump’s pivot to a more serious view of the coronavirus pandemic didn’t last long. This week, he was again touting hydroxychloroquine, an antimalarial drug that has not been shown to work against the… Read More »KHN’s ‘What The Health?’: Republicans in COVID Disarray
The companies said they had started a Phase II/III trial BNT162b2. The news comes the day after Moderna announced the launch of its Phase III study and days after Pfizer and BioNTech signed a nearly $2 billion vaccine supply deal with the federal government.
New research from MHP Health and ComRes looks at what impacts COVID-19 has had on the public’s health data sharing concerns, and asks how the industry can maintain confidence in data usage after the pandemic. In April, at the beginning of the COVID crisis, the… Read More »Brits more comfortable sharing data with pharma since COVID-19 – survey
The European Medicines Agency (EMA) has set up an infrastructure to support real-world monitoring of the efficacy and safety of COVID-19 vaccines and treatments, it was revealed in a July 21, 2020 press release. Underpinned by three contracts that EMA has signed with academic and… Read More »EMA Sets Up Infrastructure to Support Real-World Monitoring of COVID-19 Vaccines
Pfizer and BioNTech announced an agreement with the United States Department of Health and Human Services (HHS) and the Department of Defense to meet the US government s Operation Warp Speed program goal to begin delivering 300 million doses of a vaccine for COVID-19 in… Read More »Pfizer and BioNTech Sign Supply Agreement with US Government for Vaccine Candidate
New report shows more than 400 medicines and vaccines in development to tackle infectious diseases, including COVID-19
Throughout history, infectious diseases caused by pathogens such as bacteria or viruses have taken a devastating toll on the lives and security of people around the world. With the ongoing COVID-19 pandemic gripping the world, we are experiencing a challenging situation that we haven’t seen… Read More »New report shows more than 400 medicines and vaccines in development to tackle infectious diseases, including COVID-19
As the world waits anxiously for more effective COVID-19 treatments and for a vaccine to halt the pandemic, analysts on all sides are examining appropriate pricing models for these critical products. Gilead s $3000 price tag on remdesivir ($2300 for US public health programs), set… Read More »Drug Pricing Back in the Spotlight
The company announced the publication of interim data from the Phase I/II study of a vaccine it is developing with the University of Oxford. The news comes the week after Moderna announced the publication of data for its vaccine.
Amid fears of a premature emergency use authorization for a Covid-19 vaccine granted for political reasons, the guidance that the FDA released at the beginning of the month sets much tougher standards. But trial enrollment, anti-vaccine sentiment and other potential problems persist.
The Beijing company said it selected the United Arab Emirates because of its ethnic diversity, which will enable it to determine the feasibility of taking its program global. It claims that its study is the first Phase III inactivated vaccine trial, but another Chinese firm… Read More »Sinopharm launches Phase III trial of inactivated-virus vaccine in Abu Dhabi
Use Nuestro Contenido Este contenido puede usarse de manera gratuita (detalles). A más de cuatro meses del comienzo de la pandemia en los Estados Unidos, ¿qué tan cerca está el país y el mundo de una vacuna segura y efectiva? Científicos dicen que ven un… Read More »Vacuna contra el coronavirus: ¿en qué punto está la investigación?
A joint report by cybersecurity agencies in the U.K. and Canada, endorsed by their U.S. counterparts, states that the hacker group Cozy Bear had been targeting organizations involved with Covid-19 vaccine development efforts.
More than four months into the coronavirus pandemic, how close are the U.S. and the world to a safe and effective vaccine? Scientists say they see steady progress and are expressing cautious optimism that a vaccine could be ready by spring. As of early July,… Read More »A Coronavirus Vaccine: Where Does It Stand?
Global regulatory authorities have published a report describing the aligned positions on COVID-19 vaccine development, which were agreed upon by meeting participants of the second workshop on COVID-19 vaccine development convened under the umbrella of the International Coalition of Medicines Re
Evaluation of durability is still under evaluation, but the responses to mRNA-1273 show neutralizing antibody titers multiple times higher than those of recovered patients. Additionally, T-cell responses suggest potentially lower risk of enhanced respiratory disease.
PhRMA’s Lori Reilly joined CSG to discuss the industry’s response to COVID-19 and what it means for states
Recently, Lori Reilly, Chief Operating Officer at PhRMA, participated in a podcast with the Counsel of State Governments (CSG) to discuss the important work the biopharmaceutical industry is doing to combat COVID-19.
The companies anticipate releasing more clinical data from the BNT162 messenger RNA vaccine program and potentially starting a 30,000-participant Phase IIb/III study this month.
Use Nuestro Contenido Este contenido puede usarse de manera gratuita (detalles). Preocupada por el alto costo del copago por la vacuna contra el herpes zóster (culebrilla), Jacky Felder, una beneficiaria de Medicare, optó por no vacunarse el año pasado. Forma parte del grupo de Facebook… Read More »La tasa de vacunación contra la culebrilla aumenta, pero muchos quedan atrás
The NIAID create the Covid-19 Prevention Trials Network by combining four existing ones, primarily focused on HIV and AIDS, which will continue that work in addition to their new focus on Covid-19.
With more than 100 vaccine research programs looking to address the pandemic, FDA officials are moving to clarify standards and requirements for vetting and approving viable preventives. The agency recently issued a lengthy guidance outlining recommendations for documenting vaccine quality,
GlaxoSmithKline (GSK) and Medicago have announced a collaboration for the development and evaluation of a COVID-19 vaccine candidate. The collaboration was revealed in a July 7, 2020 press release. The candidate vaccine will combine Medicago s recombinant coronavirus virus-like particles (
The company is running a Phase I/II study that started in May in Australia and plans to open a Phase III study of its vaccine candidate, NVX-CoV2373, that will enroll up to 30,000 participants starting in the fall.
Novavax announced on July 7, 2020 that it has been awarded $1.6 billion from the United States federal government to participate in Operation Warp Speed, a program that intends to deliver a safe, effective vaccine for COVID-19 in 2021. The agreement will fund the late-stage… Read More »
Eating seaweed salad may boost the efficacy of vaccinations and help treat cold sores, herpes, Epstein-Barr virus, and shingles. Billions of pounds of seaweed are harvested each year, the consumption of which “has been linked to a lower incidence of chronic diseases,” both physical and… Read More »Eating Seaweed Salad May Boost Immune Function
As the world continues to feel the impact of COVID-19, the biopharmaceutical industry is working around the clock to identify and develop safe and effective vaccines to prevent infection, while also researching and developing new therapies to treat those infected with the virus. Given the… Read More »How biopharmaceutical researchers are ensuring COVID-19 vaccines will be safe and effective
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view. Today, we… Read More »Guest Post: From lab to jab: Vaccine development to prevent COVID-19
The post Five things you should know about penicillin allergies appeared first on Healthy Debate.